Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Rakovina Therapeutics Inc

Healthcare CA RKV

0.13CAD
-0.005(3.70%)

Last update at 2026-03-10T19:50:00Z

Day Range

0.130.14
LowHigh

52 Week Range

0.092.15
LowHigh

Fundamentals

  • Previous Close 0.14
  • Market Cap3.91M
  • Volume9500
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-7.34873M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.58

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -4.07262M -2.61292M -2.79123M -5.52114M -
Minority interest - - - - -
Net income -4.07262M -2.61293M -2.79123M -5.52114M -
Selling general administrative 1.45M 0.81M 0.87M 0.97M -
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 0.54M 0.54M 0.54M 0.41M -
Ebit - - - -2.47433M -0.00005M
Ebitda - - -2.28137M -2.06160M -
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income -3.78805M -2.48210M -2.81748M -2.47433M -
Other operating expenses - - - - -
Interest expense 0.27M 0.15M - 0.00000M 0.00000M
Tax provision - - - - -
Interest income 0.00582M 0.02M 0.03M 0.00854M -
Net interest income -0.26272M -0.12894M 0.03M 0.00854M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - -
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M -
Total operating expenses 3.79M 2.48M 2.82M 2.47M -
Cost of revenue - - - - -
Total other income expense net -0.02185M -0.00188M -0.00203M -3.05535M -
Discontinued operations - - - - -
Net income from continuing ops -4.07262M -2.61292M -2.79123M -5.52114M -
Net income applicable to common shares - - - -5.52114M -0.00005M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 6.24M 5.15M 6.12M 8.66M -
Intangible assets 3.98M 4.52M 5.05M 5.59M -
Earning assets - - - - -
Other current assets - - - - -
Total liab 1.94M 1.49M 0.11M 0.11M -
Total stockholder equity 4.30M 3.66M 6.01M 8.54M -
Deferred long term liab - - - - -
Other current liab - - - 0.07M 0.00002M
Common stock - - - 13.57M 0.00000M
Capital stock 16.45M 13.60M 13.58M 13.57M -
Retained earnings -14.99793M -10.92531M -8.31239M -5.52115M -0.00001M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 1.31M 0.44M 0.90M 2.81M -
Cash and equivalents - - - - -
Total current liabilities 1.94M 0.15M 0.11M 0.11M 0.00002M
Current deferred revenue - - - - -
Net debt 0.11M 0.90M - - -
Short term debt - - - - -
Short long term debt 1.42M - - - -
Short long term debt total - - - - -
Other stockholder equity - - - - -
Property plant equipment - - - - -
Total current assets 2.26M 0.63M 1.07M 3.07M 0.00001M
Long term investments - - - - -
Net tangible assets - - - 2.96M -0.00001M
Short term investments - - - - -
Net receivables 0.08M 0.02M 0.01M 0.07M 0.00000M
Long term debt - 1.33M - - -
Inventory - - - - -
Accounts payable 0.42M 0.08M 0.03M 0.04M -
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 3.98M 4.52M 5.05M 5.59M -
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments - - 0.00000M 0.80M -
Change to liabilities - - - 0.04M 0.00000M
Total cashflows from investing activities - - - 0.80M 0.80M
Net borrowings 0.00000M 1.51M - - -
Total cash from financing activities 4.73M 1.40M 0.00215M 4.32M 0.00008M
Change to operating activities - - - -0.11111M -0.11111M
Net income -4.07262M -1.78791M -2.79123M -5.52114M -0.00005M
Change in cash 0.88M -0.46052M -1.91471M 2.81M 0.00003M
Begin period cash flow 0.44M 0.90M 2.81M 0.00001M 0.00001M
End period cash flow 1.31M 0.44M 0.90M 2.81M 0.00001M
Total cash from operating activities -3.85514M -1.86171M -1.91686M -2.30818M -0.00005M
Issuance of capital stock 4.92M 0.00000M 0.00000M 4.29M -
Depreciation 0.54M 0.54M 0.54M 0.41M 0.41M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - -0.00683M 0.06M -0.07402M -0.07402M
Sale purchase of stock - - - - -
Other cashflows from financing activities - - - - 0.00008M
Change to netincome - - - 2.95M 2.95M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.55087M 0.02M 0.08M -0.14547M -
Stock based compensation 0.08M 0.13M 0.26M 0.37M -
Other non cash items 0.13M 0.06M - 2.58M -
Free cash flow -3.85514M -1.86171M -1.91686M -2.30818M -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
RKV
Rakovina Therapeutics Inc		 -0.005 3.70% 0.13 - - - 2.02 -3.3947
NGEN
NervGen Pharma Corp		 -0.11 1.96% 5.50 - - - 189.48 -4.5367
SHRX
Sharp Therapeutics Corp.		 - -% 2.25 - - - 37.28
ARCH
Arch Biopartners Inc		 -0.01 1.30% 0.76 - - 196.47 - 53.05 -97.5918
NRX
NurExone Biologic Inc.		 -0.02 3.33% 0.58 - 6.90 - 31.03 -7.2365

Reports Covered

Stock Research & News

View All

Profile

Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company's preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors. It has a research collaboration with Variational AI Inc. to identify and develop novel small-molecule therapies against DNA-damage response (DDR) targets for the treatment of cancer. Additionally, it signed a letter of intent with NanoPalm Ltd. to form a joint venture to co-develop novel small-molecule oncology therapeutics. The company was formerly known as Vincero Capital Corp. Rakovina Therapeutics Inc. is headquartered in Vancouver, Canada.

Rakovina Therapeutics Inc

999 West Broadway, Vancouver, BC, Canada, V5Z 1K5

Key Executives

Name Title Year Born
Mr. Jeffrey A. Bacha B.Sc., M.B.A. Exec. Chairman 1968
Dr. Mads Daugaard Pres & Chief Scientific Officer NA
Mr. David Hyman CA, CBV CFO & Corp. Sec. 1973
Dr. John Langlands Ph.D. Chief Operating Officer NA
Mr. Jeffrey A. Bacha B.Sc., M.B.A. Executive Chairman 1968
Dr. Mads Daugaard Ph.D. President, CEO & Chief Scientific Officer NA
Mr. David Hyman CA, CBV CFO & Corporate Secretary 1973
Dr. David M. Kideckel M.B.A., MBA, Ph.D. CFO & Director 1981
Ms. Michelle Seltenrich M.B.A., MBA Director of Corporate Development NA
Dr. David M. Kideckel M.B.A., Ph.D. CFO & Director 1980

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.